A biotech investor funds a gene therapy project where each successful trial enables two new trials the next year. Starting with 3 initial trials, how many trials occur in year 5?

Thu, 30 Apr 2026 11:37:08 +0000

**Why Gene Therapy Projects Are Reshaping Biotech Investment—And How Trials Multiply Year by Year** In an era where medical innovation moves faster than ever, a breakthrough funding model is turning heads: a forward-looking biotech investment strategy where each successful gene therapy trial funds not just the next experiment, but two new trials the following year. Starting with just three trials, this cascading approach reflects a growing trend in biotech capital allocation—where success directly powers future progress. What began as a single pilot is now sparking discussions about scalable, self-sustaining research ecosystems. How this model unfolds over five years reveals unexpected growth patterns shaped by biology, economics, and patient hope. Understanding this growth starts with a clear pattern: year after year, every current trial fuels subsequent opportunities. As one leading gene therapy funder explains, this model accelerates development by turning clinical wins into exactly twice as much future capacity. With three starting trials, the structure creates exponential momentum—gentle at first, yet compounding rapidly in year five. ### Why This Gene Therapy Model Is Gaining Traction in the U.S.